InvestorsObserver
×
News Home

Should You Buy Cyclacel Pharmaceuticals Inc (CYCC) Stock on Thursday?

Thursday, February 18, 2021 11:42 AM | InvestorsObserver Analysts

Mentioned in this article

Should You Buy Cyclacel Pharmaceuticals Inc (CYCC) Stock on Thursday?

Overall market sentiment has been down on Cyclacel Pharmaceuticals Inc (CYCC) stock lately. CYCC receives a Bearish rating from InvestorsObserver's Stock Sentiment Indicator.

Sentiment Score - ,bearish
Cyclacel Pharmaceuticals Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on CYCC!

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.

Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.

InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.

For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With CYCC Stock Today?

Cyclacel Pharmaceuticals Inc (CYCC) stock is trading at $8.40 as of 11:37 AM on Thursday, Feb 18, a loss of -$0.55, or -6.15% from the previous closing price of $8.95. The stock has traded between $8.02 and $8.82 so far today. Volume today is less active than usual. So far 259,048 shares have traded compared to average volume of 1,022,760 shares.

To see InvestorsObserver's Sentiment Score for Cyclacel Pharmaceuticals Inc click here.

More About Cyclacel Pharmaceuticals Inc

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include CYC065 CDK inhibitor, Sapacitabine and seliciclib, CYC682, CYC140 PLK inhibitor, and CYC202. It earns the majority of its revenue from the United Kingdom.

Click Here to get the full Stock Score Report on Cyclacel Pharmaceuticals Inc (CYCC) Stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App